GONCAGUL AKDAG, AKİF DOGAN, SEDAT YİLDİRİM, OGUZCAN KİNİKOGLU, EMRE KUDU, HEVES SURMELİ, DENİZ ISİK, OZLEM NURAY SEVER, HATİCE ODABAS, MAHMT EMRE YİLDİRİM, NEDİM TURAN
Eurasian Journal of Medical Investigation - 2024;8(3):212-219
Objectives: Breast cancer (BC) is the most commonly malignancy in women. The emergence of cyclin-dependent ki nase inhibitors (CdK 4/6i) has significantly improved prognosis. Until now, no predictive factor of response to CdK4/6i has been identified. This study investigates the relationship between ABO and Rhesus (D) groups and the therapeutic response to CdK4/6i. Methods: This retrospective study registered records of mBC treated with CdK 4/6i at the Kartal Dr. Lutfi Kirdar City Hospital. Results: The study comprised 185 metastatic BC patients. During the study period, 32 patients (17.3%) died. The me dian overall survival (OS) was 18.3 months. The A group had the highest number of deaths (n=16), while the B group had the highest death rate proportionally (23.0%). Interestingly, no deaths were observed in the AB group. Disease progression was observed in 84 patients (45.4%). An analysis of the average progression-free survival (PFS) showed that patients with group O was PFS of 37.8 months (95% Confidence Interval (CI): 31.0-44.6), group A was 19.7 months (95% CI: 16.6-22.8), group B was 19.6 months (95% CI: 14.3-24.8), and group AB was 14.2 months (95% CI: 28.5-36.8). No statistically significant difference was observed when an OS (p=0.23) and PFS (p=0.138) analysis was performed ac cording to ABO groups. In the univariate analysis, the Rh factor did not serve as a prognostic factor on either PFS or OS. Conclusion: We found no prognostic effect of blood group or Rh status on overall survival and progression-free sur vival in patients.
